Lifesci Capital Has Strong Forecast for DBVT FY2026 Earnings

DBV Technologies S.A. (NASDAQ:DBVT) – Equities research analysts at Lifesci Capital increased their FY2026 EPS estimates for DBV Technologies in a research note issued to investors on Monday, March 30th. Lifesci Capital analyst S. Slutsky now forecasts that the company will post earnings per share of ($0.64) for the year, up from their previous forecast of ($1.95). The consensus estimate for DBV Technologies’ current full-year earnings is ($7.05) per share.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Saturday, February 14th. The company reported ($1.15) EPS for the quarter. The firm had revenue of $0.65 million during the quarter. DBV Technologies had a negative net margin of 2,606.83% and a negative return on equity of 189.17%.

A number of other brokerages have also commented on DBVT. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Cantor Fitzgerald set a $48.00 target price on shares of DBV Technologies in a research report on Wednesday, December 17th. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th. Citizens Jmp raised their price target on shares of DBV Technologies from $45.00 to $47.00 and gave the stock a “market outperform” rating in a research report on Friday, March 27th. Finally, HC Wainwright set a $40.00 price objective on shares of DBV Technologies in a report on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $38.65.

DBV Technologies Trading Down 1.9%

NASDAQ:DBVT opened at $20.50 on Wednesday. The stock has a 50 day simple moving average of $21.53 and a 200 day simple moving average of $17.50. The stock has a market cap of $1.14 billion, a P/E ratio of -3.93 and a beta of -0.94. DBV Technologies has a 1-year low of $6.00 and a 1-year high of $26.18.

Institutional Trading of DBV Technologies

A number of institutional investors have recently modified their holdings of the stock. Allworth Financial LP bought a new position in shares of DBV Technologies in the fourth quarter worth $32,000. Royal Bank of Canada acquired a new position in DBV Technologies in the fourth quarter valued at about $34,000. GAMMA Investing LLC lifted its position in DBV Technologies by 38.4% during the fourth quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock worth $51,000 after purchasing an additional 744 shares during the period. New York State Common Retirement Fund bought a new stake in DBV Technologies during the third quarter worth about $34,000. Finally, Truvestments Capital LLC grew its stake in DBV Technologies by 71.3% during the fourth quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock worth $75,000 after buying an additional 1,620 shares in the last quarter. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.